Skip to main content

Botulinum Toxin A Injections for Reduction of Facial Rhytids

  • Chapter
  • First Online:
Primary Care Procedures in Women's Health
  • 875 Accesses

Abstract

Botulinum Toxin A, commonly known as Botox® or Botox® Cosmetic (both: Allergan, Irvine, CA) or Dysport (Medicis, USA), is a neurotransmitter blocker that is used in aesthetic procedures to erase the fine lines of the face known as active lines. The mechanism of action of this drug is to block neurotransmitters in the facial muscles by binding the muscle receptor site on the muscles necessary to make the muscle fire. Botox® or Botox® cosmetic take approximately 2–7 days to work their way into the muscle and remain tightly bound to the muscles for approximately 3–5 months, whereas Dysport takes effect in 1.5 days and remains effective for 4–6 months. Botox has been available for use in the US since the early 70s. Dysport was approved for cosmetic use by the FDA in 2009. It has however, been in use for cosmetic purposes in Europe under the trade name Reloxin for approximately 20 years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin A in the treatment of glabellar rhytids in females. Dermatol Surg 2005;31:414–422.

    Article  PubMed  CAS  Google Scholar 

  2. Hexsel DM, Trinidad De Almeida A, Rutowitsch M, Alencar De Castro I, Silveria VLB, Gobatto DO, Zechmeister M, Mazzuco R, Zechmeister D. Multicenter, double-blind study of the efficacy of injections with botulinum toxin A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003;29:523–529.

    Article  PubMed  Google Scholar 

  3. Brandt F, Swanson N, Baumann L, A phase III, randomized double blind, Placebo-Controlled study to assess the efficacy and safety of reloxin® in the treatment of glabellar lines. Presented at the 31st Hawaii dermatology seminar March 3–9, 2007 Maui, HI.

    Google Scholar 

  4. Moy R, Maas C, Monheit G, Huber B, Reloxin investigational group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sharon D. Gertzman .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gertzman, S.D. (2010). Botulinum Toxin A Injections for Reduction of Facial Rhytids. In: Sulik, S., Heath, C. (eds) Primary Care Procedures in Women's Health. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76604-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-76604-1_28

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-76598-3

  • Online ISBN: 978-0-387-76604-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics